Progression of Early Subclinical Atherosclerosis (PESA)

This study is currently recruiting participants.
Verified August 2011 by Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
Sponsor:
Collaborators:
Banco Santander
Ministerio de Ciencia e Innovación, Spain
Fundación Botín
Instituto de Salud Carlos III
Fundaciónprocnic
Information provided by (Responsible Party):
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
ClinicalTrials.gov Identifier:
NCT01410318
First received: August 2, 2011
Last updated: February 21, 2013
Last verified: August 2011

August 2, 2011
February 21, 2013
June 2010
June 2019   (final data collection date for primary outcome measure)
Presence of subclinical atherosclerotic disease in any imaging test; Basic imaging tests (ankle/brachial blood pressure, carotid ultrasound, abdominal aorta ultrasound and CT for calcium scoring) and advanced imaging tests (MRI and PET) [ Time Frame: 6 years ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01410318 on ClinicalTrials.gov Archive Site
Prevalence of unrecognized myocardial infarction and its relationship to risk factors. [ Time Frame: 6 years ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Progression of Early Subclinical Atherosclerosis
Early Detection and Progression of Subclinical Atherosclerosis and Its Relationship to Coronary Risk Factors

The overall objective of this study is to characterize the prevalence and progression rate of subclinical atherosclerotic lesions and to study their association to the imaging characteristics of atheroma plaques and to the presence of genetic, epigenetic, metabolomic, and environmental factors, including dietary habits, physical activity, biorhythms, psychosocial characteristics, and exposure to environmental pollutants

Atherosclerosis is the most common cardiovascular disease and accounts for the greatest number of deaths. Atherosclerotic disease starts at an early age and follows a subclinical course for decades, becoming apparent in the fifth or sixth decades of life in men and approximately 10 years later in women. Its main clinical signs include myocardial infarction, angina pectoris, sudden death, or stroke. Disease occurrence and progression are conditioned by the presence of the so-called risk factors: smoking, dyslipidemia, hypertension, and diabetes, among others. From these factors, a number of equations have been developed for predicting the risk of an individual to suffer the disease, in order to apply adequate prevention measures such as lifestyle changes or drug treatment. However, despite the proven efficacy of such interventions, cardiovascular prevention has many limitations due to three significant problems:

  1. The ability to predict risk from current equations is very limited because other genetic or environmental factors that may influence the course of disease are still unknown.
  2. The ability for early prediction of cardiovascular risk from current equations is even more limited in individuals under 55 years of age.
  3. Atherosclerotic disease is diagnosed too late, usually when the condition is very advanced and lesions are already irreversible, or when it has caused clinical signs or events in organs or territories vascularized by the diseased arteries. Clinical procedures currently used for detection of myocardial ischemia are however poorly sensitive and specific in the asymptomatic general population.

Technological advances made in the past decade in both laboratory tests and medical imaging have opened up new expectations for detection and treatment of atherosclerotic disease. Current research is focused on two aspects:

  1. To improve the ability to predict the disease by incorporating risk factors obtained from the laboratory such as C-reactive protein, homocysteine, fibrinogen, myeloperoxidase, or lipoprotein-associated phospholipase A2. At the same time, development of genetics and the new so-called "omics" techniques allows for exploring the genetic variability of individuals and its contribution to development of the disease and its complications. Such technologies include genomics, epigenomics, transcriptomics, proteomics, and metabolomics.
  2. To detect the disease at an early stage using the advanced imaging techniques, which may be used with no or minimal risks in large population groups. Use of magnetic resonance imaging (MRI) with and without contrast, computed tomography (CT), and positron emission tomography (PET) allows not only for identifying subclinical lesions, but also for studying the mechanisms of disease and for monitoring its course.

Very few population studies making combined use of some of these procedures are available. The actual potential of this approach and the impact it may have on early diagnosis of subclinical atherosclerosis, its progression, and its relationship to risk factors have not been assessed to date.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:
  • Orine (4 x 5 mL)
  • Blood (8 x 0.6 mL)
  • Serum (8 x 0.6 mL)
  • EDTA plasma (8 x 0.6 mL)
  • Buffy Coat (2 x 0.6 mL)
  • Non insultated RNA (2 x 5 mL PAXgene)
  • Insulated DNA (2 x 0.3 mL, 150 ng/microL + 1 x 0.3 mL, 75 ng/microL)
Non-Probability Sample

The target population of the study consists of employees (N= 4000) of the Banco de Santander Group in the Madrid region (65% males and 35% females, aged 40-54 years).

Atherosclerosis
Not Provided
Not Provided
Fernández-Ortiz A, Jiménez-Borreguero LJ, Peñalvo JL, Ordovás JM, Mocoroa A, Fernández-Friera L, Laclaustra M, García L, Molina J, Mendiguren JM, López-Melgar B, de Vega VM, Alonso-Farto JC, Guallar E, Sillesen H, Rudd JH, Fayad ZA, Ibañez B, Sanz G, Fuster V. The Progression and Early detection of Subclinical Atherosclerosis (PESA) study: rationale and design. Am Heart J. 2013 Dec;166(6):990-8. doi: 10.1016/j.ahj.2013.08.024. Epub 2013 Oct 10.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
4000
June 2019
June 2019   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Employees of the Banco de Santader Group
  • Age between 40-54 years.

Exclusion Criteria:

  • Myocardial Infarction
  • Angina pectoris
  • Stroke, either transient or with sequelae
  • Peripheral vascular disease
  • Prior angioplasty or heart surgery
  • Atrial fibrillation
  • Other heart diseases

Subjects with the following conditions will also be excluded:

  • Pregnancy
  • Active treatment for any cancer
  • Morbid obesity (BMI ≥40)
  • Renal failure with creatinine clearance <60 mL/min, as estimated by the Cockcroft and Gault formula
  • Any disease that decreases life expectation to ≤6 years
  • Pacemaker, implantable automatic defibrillator, or any implanted device that contraindicates MRI
  • A chest CT in the previous year
Both
40 Years to 54 Years
Yes
Contact: Borja Ibáñez, PhD 0034 91 453 12 00 ext 4302 bibanez@cnic.es
Contact: Eliseo Guallar, PhD 0034 91 453 12 00 ext 4102 eguallar@cnic.es
Spain
 
NCT01410318
PESA CNIC-SANTANDER
Yes
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
  • Banco Santander
  • Ministerio de Ciencia e Innovación, Spain
  • Fundación Botín
  • Instituto de Salud Carlos III
  • Fundaciónprocnic
Principal Investigator: Valentín Fuster, PhD Centro Nacional de Investigaciones Cardiovasculares Carlos III
Study Director: Eliseo Guallar, PhD Centro Nacional de Investigaciones Cardiovasculares Carlos III
Study Director: Borja Ibañez, PhD Centro Nacional de Investigaciones Cardiovasculares Carlos III
Study Director: Manuel Franco, PhD Centro Nacional de Investigaciones Cardiovasculares Carlos III
Study Chair: Ginés Sanz, PhD Centro Nacional de Investigaciones Cardiovasculares Carlos III
Study Chair: Jose María Ordovás, PhD Centro Nacional de Investigaciones Cardiovasculares Carlos III
Study Chair: Luis Jesús Jiménez Borreguero, MD Centro Nacional de Investigaciones Cardiovasculares Carlos III
Study Chair: Jose Luis Peñalvo, PhD Centro Nacional de Investigaciones Cardiovasculares Carlos III
Study Chair: Martín Laclaustra, PhD Centro Nacional de Investigaciones Cardiovasculares Carlos III
Study Chair: Ana Dopazo, PhD Centro Nacional de Investigaciones Cardiovasculares Carlos III
Study Chair: Gabriela Guzman, PhD Centro Nacional de Investigaciones Cardiovasculares Carlos III
Study Chair: María Téllez, PhD Centro Nacional de Investigaciones Cardiovasculares Carlos III
Study Chair: Marta Tomás, MD Centro Nacional de Investigaciones Cardiovasculares Carlos III
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
August 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP